Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17)
- 1 April 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (7), 1928-1933
- https://doi.org/10.1093/jac/dkz120
Abstract
Background Despite the advances in current healthcare, bone and joint infections (BJIs) are a major clinical challenge that frequently involve prolonged systemic antibiotic use. Healthcare providers consider tedizolid an attractive candidate for therapy in adults and children with BJI. Objectives We tested tedizolid against a US and European collection of Gram-positive BJI isolates (n = 797) consecutively collected from 2014 to 2017. Methods Organisms were tested by broth microdilution susceptibility methods following current CLSI guidelines and interpreted by both CLSI and EUCAST breakpoint criteria. Results Staphylococcus aureus (59.3%; 58.6% in the USA and 60.4% in Europe) was the most common pathogen with a 29.6% MRSA rate and tedizolid MIC50/90 of 0.12/0.25 mg/L (100% susceptible). CoNS (15.0% of BJI in adults and 95%) for vancomycin, daptomycin and linezolid were observed and, based on MIC90 values, tedizolid (MIC90 0.12–0.25 mg/L) was 4- to 8-fold more potent than linezolid (MIC90 0.5–2 mg/L) against this collection of Gram-positive pathogens causing BJI. Conclusions This study showed that tedizolid had potent in vitro activity against contemporary Gram-positive cocci causing BJI in adults and children in US and European hospitals.Keywords
Funding Information
- Merck Sharp & Dohme Corp.,
This publication has 18 references indexed in Scilit:
- Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014Antimicrobial Agents and Chemotherapy, 2016
- Tedizolid: The First Once-Daily Oxazolidinone Class AntibioticClinical Infectious Diseases, 2015
- Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive PathogensDrugs, 2015
- Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2015
- Epidemiology and burden of prosthetic joint infectionsJournal of Antimicrobial Chemotherapy, 2014
- Prosthetic Joint InfectionClinical Microbiology Reviews, 2014
- Tedizolid for the Management of Human Infections: In Vitro CharacteristicsClinical Infectious Diseases, 2014
- Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure InfectionsJama-Journal Of The American Medical Association, 2013
- In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2012